FBRX
NASDAQForte Biosciences Inc.
Price$15.74-0.33 (-2.02%)
01:30 PM03:30 PM
News · 26 weeks38+57%
2025-12-142026-06-07
Mix2990d
- SEC Filings12(41%)
- Insider8(28%)
- Other7(24%)
- Offering2(7%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Forte Biosciences Inc.SCHEDULE 13G - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form S-3/A filed by Forte Biosciences Inc.S-3/A - Forte Biosciences, Inc. (0001419041) (Filer)
- INSIDERSEC Form 4 filed by Director Doberstein Stephen K4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SECSEC Form S-3 filed by Forte Biosciences Inc.S-3 - Forte Biosciences, Inc. (0001419041) (Filer)
- INSIDERSEC Form 4 filed by Director Kapoor Shivpreet Singh4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Vincent Richard G4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Gryska David W4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Brun Scott C.4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Kornfeld Steven4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SECSEC Form S-8 filed by Forte Biosciences Inc.S-8 - Forte Biosciences, Inc. (0001419041) (Filer)
- SECForte Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Forte Biosciences, Inc. (0001419041) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECForte Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Forte Biosciences, Inc. (0001419041) (Filer)
- PRForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual accepting employment with the Company. The option award shal
- SECSEC Form 10-Q filed by Forte Biosciences Inc.10-Q - Forte Biosciences, Inc. (0001419041) (Filer)
- PRForte Biosciences, Inc. Announces First Quarter 2026 Results and Provides UpdateFB102 Received Fast Track Designation in Celiac Disease Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026 financial results and provided a business update. "FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102's potential to address the high unmet need in celiac disease. The clinical development for FB102 continues to progress well with important readouts coming shortly," said Forte Biosciences CEO Paul Wagner, PhD. "The topline results from our phase 2 celiac disease study ar
- SECSEC Form DEF 14A filed by Forte Biosciences Inc.DEF 14A - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form 424B5 filed by Forte Biosciences Inc.424B5 - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form 8-K filed by Forte Biosciences Inc.8-K - Forte Biosciences, Inc. (0001419041) (Filer)
- PRForte Biosciences Announces Pricing of $150 Million Public OfferingForte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Forte. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offe
- SECSEC Form 424B5 filed by Forte Biosciences Inc.424B5 - Forte Biosciences, Inc. (0001419041) (Filer)
- PRForte Biosciences Announces Proposed Public OfferingForte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock. All of the shares of common stock are being offered by Forte. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Forte intends to use the net proceeds of the offering for w
- INSIDERSEC Form 4 filed by Riley Antony A4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Wagner Paul A.4 - Forte Biosciences, Inc. (0001419041) (Issuer)
FBRX FAQ
7 questionsWhat does Forte Biosciences Inc. do?
Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.Where does FBRX stock trade?
Forte Biosciences Inc. (FBRX) is listed on NASDAQ.What sector and industry is FBRX in?
Forte Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Forte Biosciences Inc. go public?
Forte Biosciences Inc. (FBRX) completed its IPO in 2017.What are analysts saying about FBRX?
Forte Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2025-11-25. Recent price targets range from $275.00 to $350.00.What companies are similar to FBRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare FBRX side-by-side with any of them on Quantisnow.How can I track FBRX on Quantisnow?
Quantisnow aggregates Forte Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FBRX to receive live email and push alerts on every new disclosure.